This study is a single-arm, open-label clinical trial designed to evaluate the safety and tolerability of DIT101 in adults with relapsed or refractory hematologic malignancies and to explore its potential anti-tumor effects.

DIT101 is an investigational in vivo CAR-T cell therapy administered by intravenous infusion. After administration, it is intended to generate CAR-T cells within the patient's body that can recognize and attack tumor cells. Unlike approved autologous CAR-T therapies, DIT101 does not require collection and ex vivo genetic modification of the participant's own cells.

The study includes a screening period, DIT101 infusion treatment, a post-treatment intensive follow-up period of approximately 6 months, and a long-term follow-up period of up to 2 years, with visits every 3-6 months.

Inclusion Criteria:

• Adults aged 18 to <70 years, any gender.

• Voluntarily provide written informed consent and willing to comply with all study procedures.

• Diagnosed with relapsed or refractory B-cell acute lymphoblastic leukemia/lymphoma (B-ALL/LBL), or other relapsed/refractory hematologic malignancies as judged by the investigator and confirmed by the collaborating institution.

• Tumor cells confirmed positive for the target antigen by immunophenotyping.

• Bone marrow blast ≥5% at screening and/or presence of extramedullary disease.

• For B-ALL/LBL patients, meets criteria for relapsed/refractory disease, including:

  • Primary refractory after ≥2 cycles of standard chemotherapy or not achieving CR after multiple salvage regimens;
  • Relapse within 12 months after CR or ≥12 months relapse after CR not achieving CR after subsequent standard therapy;
  • Relapse after hematopoietic stem cell transplantation;
  • Relapse after prior CAR-T therapy targeting the same antigen.

• ECOG performance status 0-2.

• Expected survival >3 months.

• Adequate organ function, including:

  • Renal: creatinine clearance >45 mL/min;
  • Hepatic: total bilirubin ≤3×ULN, ALT/AST ≤5×ULN;
  • Coagulation: PT, APTT, or INR ≤1.5×ULN;
  • Cardiac: LVEF ≥50% within 1 month;
  • Pulmonary: SpO₂ ≥92% at rest on room air;
  • Hematologic and immune function considered sufficient to tolerate study treatment.

• Women of childbearing potential must have a negative pregnancy test; women considered not of childbearing potential include those who are postmenopausal for ≥12 months or have undergone surgical sterilization (hysterectomy or bilateral oophorectomy).

Exclusion Criteria:

• Pregnant or breastfeeding women.

• Known hereditary bone marrow failure syndromes (e.g., Fanconi anemia, Kostmann syndrome, Shwachman syndrome, or other known marrow failure syndromes).

• Uncontrolled active central nervous system leukemia (CNSL; CNS2 or CNS3).

• Prior anti-cancer therapy before screening, including:

  • Systemic chemotherapy within 1 week;
  • Systemic immunotherapy/targeted therapy (monoclonal antibodies, bispecific antibodies, ADCs, etc.) with last dose <5 half-lives or <4 weeks (whichever is shorter);
  • Donor lymphocyte infusion within 6 weeks;
  • CAR-T therapy or hematopoietic stem cell transplantation within 3 months;
  • Radiotherapy within 4 weeks (unless bone marrow reserve >5% and investigator judges it does not affect eligibility);
  • Persistent clinically significant toxicity from prior therapy not recovered to ≤CTCAE Grade 1 (except alopecia).

• Uncontrolled severe active infection.

• History of significant cardiac disease, including: severe heart failure (NYHA class III-IV), myocardial infarction or PCI/stent within 12 months, unstable angina, QTc >480 ms, or other clinically significant arrhythmia per investigator judgment.

• History of CNS injury, seizure, stroke, or brain hemorrhage requiring treatment within 6 months.

• Active viral infections:

  • HIV antibody positive, syphilis serology positive;
  • HBsAg >10⁶ IU/mL;
  • HCV antibody positive;
  • EBV positive (EBER or copy number above normal).

• Need for long-term systemic corticosteroid therapy during DIT-101 infusion (local or inhaled steroids allowed).

• Active autoimmune disease requiring treatment, immunodeficiency, or use of immunosuppressive therapy.

• Acute or moderate-to-severe chronic graft-versus-host disease (GvHD) within 4 weeks prior to screening.

• Known severe allergy to any component of DIT-101.

• Women of childbearing potential or men unable to use effective contraception during DIT-101 infusion and for 1 year post-infusion; plans for pregnancy within 1 year post-infusion in male or female subjects or their partners.

• Any condition that, in the investigator's opinion, may increase risk or interfere with study outcomes.

• Prior malignancy other than hematologic malignancy, except:

  • Malignancy treated with curative intent and disease-free ≥2 years;
  • Non-melanoma skin cancer adequately treated with no current evidence of disease.